Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» age-related macular degeneration
age-related macular degeneration
Ionis axes eye disease from targets of Roche-partnered prospect after data disappoint
Fierce Biotech
Thu, 08/1/24 - 11:50 am
Ionis Pharmaceuticals
Roche
age-related macular degeneration
Astellas’ Izervay reduces GA lesion growth in Phase III trial
Clinical Trials Arena
Mon, 11/6/23 - 09:51 am
Astellas
Izervay
geographic atrophy
age-related macular degeneration
clinical trials
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Thu, 08/10/23 - 09:49 pm
Regeneron
Eylea
age-related macular degeneration
FDA
Things don't look good for NGM's Merck-partnered eye asset as phase 2 fail sends stock plummeting
Fierce Biotech
Mon, 10/17/22 - 11:17 pm
NCM Biopharmaceuticals
clinical trials
Merck
age-related macular degeneration
Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
Fierce Pharma
Mon, 11/15/21 - 11:51 pm
Apellis Pharmaceuticals
pegcetacoplan
FDA
clinical trials
age-related macular degeneration
Gemini axes CSO and 20% of staff to focus on late-phase plans
Fierce Biotech
Tue, 10/5/21 - 10:43 am
Gemini Therapeutics
layoffs
gene therapy
CSO
age-related macular degeneration
FDA approves first biosimilar to top-selling eye drug Lucentis
BioPharma Dive
Mon, 09/20/21 - 10:55 pm
FDA
biosimilars
Lucentis
age-related macular degeneration
Byooviz
Biogen
Samsung Bioepis
Outlook heads to regulators with eye-friendly Avastin
EP Vantage
Wed, 08/4/21 - 10:53 am
Outlook Therapeutics
Avastin
age-related macular degeneration
FDA
Lucentis
3 Biotech Stocks With Big Catalysts in June
Motley Fool
Tue, 06/22/21 - 10:55 am
Corbus Pharmaceuticals
lenabasum
clinical trials
Gemini Therapeutics
age-related macular degeneration
Intellia Therapeutics
hATTR-pn
Gyroscope bags $148M for AMD gene therapy trials, mulls IPO
Fierce Biotech
Fri, 03/26/21 - 10:53 am
Gyroscope
gene therapy
IPOs
age-related macular degeneration
Genentech Could Regain the Blindness-Related Disease Market with New Treatment
BioSpace
Sat, 02/13/21 - 11:01 pm
Roche
Genentech
clinical trials
faricimab
age-related macular degeneration
nAMD
RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration
Pharmaceutical Business Review
Wed, 03/18/20 - 10:17 am
RIBOMIC
AJU Pharm Co
Korea
RBM-007
age-related macular degeneration
3 Biotech Stocks That Soared Last Week
Motley Fool
Sun, 09/15/19 - 09:51 pm
Acadia Pharmaceuticals
Nuplazid
Mesoblast
Grunenthal
MPC-06-ID
Kodiak Sciences
age-related macular degeneration
Novartis backs brolucizumab with new head-to-head Eylea trial
Pharmaforum
Mon, 09/9/19 - 08:15 pm
Novartis
clinical trials
brolucizumab
Eylea
Bayer
Regeneron
age-related macular degeneration
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
An eye drop for macular degeneration shows promise in animal studies
Fierce Biotech
Fri, 07/20/18 - 09:44 am
age-related macular degeneration
Macregen
Apellis touts new data for eye drug hopeful
Biopharma Dive
Sun, 02/25/18 - 11:22 am
Apellis
eye health
APL-2
age-related macular degeneration
LumiThera wins Health Canada nod for photobiomodulation trial
Mass Device
Fri, 03/25/16 - 09:36 am
LumiThera
Canada
photobiomodulation
devices
age-related macular degeneration
The Next Blockbusters Could Be Balms For Aging Eyes
Investors.com
Thu, 09/3/15 - 09:10 am
age-related macular degeneration
Bayer
Regeneron
Ophthotech
Allergan
Novartis
Applied Genetic Technologies
Avalanche Biotechnologies
Roche
Lucentis
Eylea
Italy's move to fund unapproved use of Roche's Avastin alarms the industry
Fierce Pharma
Wed, 06/11/14 - 10:47 am
Italy
Roche
Avastin
age-related macular degeneration
Pages
1
2
3
next ›
last »